Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: An event-related potential study

Pharmacology Biochemistry and Behavior

Volumn 72, Issue 1-2, 2002, Pages 457-464

  Engeland, C ^a   Mahoney, C ^b   Mohr, E ^c   Ilivitsky, V ^b   Knott, Verner J ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c PRA International USA   (Netherlands)

Author keywords

Acetylcholine; Alzheimer's disease; ERPs, Event related potentials; MMN, Mismatch negativity; Nicotine; Sensory memory; Tacrine

Indexed keywords

NICOTINE GUM; TACRINE; NICOTINE;

ADULT; AGED; ALZHEIMER DISEASE; AMPLITUDE MODULATION; ARTICLE; AUDITORY DISCRIMINATION; AUDITORY STIMULATION; AUDITORY SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EVENT RELATED POTENTIAL; FEMALE; HUMAN; LATENT PERIOD; MALE; MEMORY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STIMULUS RESPONSE; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; EVOKED AUDITORY RESPONSE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ACOUSTIC STIMULATION; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NICOTINE; TACRINE;

EID: 0036204615     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(02)00711-6     Document Type: Article

References (75)

1. The P300 brain potential is reduced in smokers
2. The cholinergic hypothesis of geriatric memory dysfunction
3. Evidence that tobacco smoking increases the density of (-) [3H] nicotine binding sites in human brain
4. Mismatch negativity in event-related potentials to auditory stimuli: As a function of varying interstimulus interval
5. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys
6. Selective loss of central cholinergic neurons in Alzheimer's disease
7. Electrophysiological models for the study of cognitive enhancers
8. The organization of short-term memory for a single acoustic attribute
9. Event-related potentials and psychopharmacology: Cholinergic modulation of P300
10. Smoking, nicotine and psychiatric disorders: Evidence for therapeutic role, complications and implications for future research
11. Evidence of a more rapid stimulus evaluation following cigarette smoking
12. Short-term replicability of the mismatch negativity
13. Neural mechanisms of involuntary attention to acoustic novelty and change
14. 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician
15. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers
16. Changes in sensitivity to stimulus deviance in Alzheimer's disease: An ERP perspective
17. Possible roles for mismatch negativity in neuropsychiatry
18. Therapy for Alzheimer's disease: Symptomatic or neuroprotective?
19. Alzheimer disease, from molecular biology to therapy
20. 7: Electrophysiological models for the study of cognition enhancers
21. Nicotine and smoking: A review of effects on human performance
22. Faster P300 latency after smoking in visual but not auditory oddball tasks
23. The time course effects of smoking on stimulus evaluation and response selection
24. Low dose of ethanol suppresses mismatch negativity of auditory event-related potentials
25. Dose-related effect of alcohol on mismatch negativity and reaction time performance
26. Efficacy of transdermal nicotine using event-related potentials and middle latency response
27. Mismatch negativity during attend and ignore conditions in Alzheimer's disease
28. Cigarette smoking and event-related brain electric potential topographics associated with attentional-distractional processes
29. Transdermal nicotine: Single dose effects on mood, EEG, performance, and event-related potentials
30. EEG and the passive P300 in dementia of the Alzheimer type
31. Augmenting mental chronometry: The P300 as a measure of stimulus evaluation time
32. Alzheimer disease, attention and the cholinergic system
33. Nicotine: Abused substance and therapeutic agent
34. A low dose of subcutaneous nicotine improves information processing in non-smokers
35. Nicotinic systems and cognitive function
36. On the dependence of P300 latency on stimulus evaluation processes
37. Use of endogenous event-related potentials (ERPs) in the evaluation of psychotropic substances: Towards an ERP profile of drug effects
38. In search for short-duration memory trace of a stimulus in the human brain
39. The NI wave of the human electric and magnetic response to sound: A review and analysis of the component structures
40. Early selective attention affect reinterpreted
41. Intravenous nicotine in Alzheimer's disease: A pilot study
42. Neuroendocrine, physiologic, and behavioural response following intravenous nicotine in non-smoking healthy volunteers and in patients with Alzheimer's disease
43. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography
44. Mismatch negativity and age-related auditory memory
45. Auditory sensory memory impairment in Alzheimer's disease: An event-related potential study
46. Variability and replicability of the mismatch negativity
47. Aging effects on auditory processing: An event-related potential study
48. Correlation of cholinergic abnormalities with senile plagues and mental test scorer in senile dementia
49. Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic and decarboxylase activities in necropsy brain tissue
50. The P300 wave of the human event-related potential
51. P300 clinical utility and control of variability
52. Cognitive and biological determinants of P300: An integrative review
53. P300 assessment of early Alzheimer's disease
54. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-318 in Alzheimer's disease
55. Effects of nicotine on human performance
56. Effects of nicotine gum on repeated administration of the Stroop Test
57. Twenty years of cholinergic intervention in Alzheimer's disease; a tale of disappointment and ultimate confidence
58. THA disrupts mismatch negativity in Alzheimer disease
59. Subchronic treatment of rats with nicotine: Interconversion of nicotine receptor subtypes
60. Plasma nicotine levels of ten cigarette smoking and chewing nicotine gum
61. Nicotine and tetrahydroaminoacridine: Evidence for improved attention in patients with dementia of the Alzheimer type
62. The effects of nicotine in attention, information processing and short-term memory in patients with dementia of the Alzheimer type
63. Nicotinic cholinergic receptor binding sites in the brain: Regulation in vivo
64. A solution for reliable and valid reduction of ocular artifacts applied to the P300 ERP
65. Psychomotor performance in smokers following single and repeated doses of nicotine gum
66. Neuronal nicotinic receptor activation: A promising strategy for treatment of Alzheimer's disease
67. Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex
68. Differential responsivity of mood behavior and cognition to cholinergic agents in elderly neuropsychiatric patients
69. On the utility of P3 latency as an index of mental chronometry
70. Smoking, nicotine and human performance
71. Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
72. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
73. Effects of nicotinic agonists and antagonists on spatial working memory in normal adult and aged rats